+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction



Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction



American Journal of Transplantation 2(7): 671-673



Treatment regimens of patients with active cytomegalovirus (CMV) disease require 2-3 weeks of intravenous ganciclovir (GCV) with/without CMV hyperimmune globulin. Oral GCV is effective as a prophylactic agent in prevention of CMV disease. Here we explored the utility of oral GCV as a treatment of active CMV disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 003993023

Download citation: RISBibTeXText

PMID: 12201370

DOI: 10.1034/j.1600-6143.2002.20714.x


Related references

Treatment of active CMV infection in renal allograft recipients with oral ganciclovir Monitoring efficacy using quantitative CMV-PCR. Journal of Investigative Medicine 49(1): 48A, 2001

Treatment of active CMV infection with oral ganciclovir in renal allograft recipients Monitoring efficacy with quantitative CMV-PCR. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 719A-720A, 2000

Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. Journal of Infectious Diseases 178(3): 626-635, 1998

Diagnosis of cytomegalovirus (Cmv) disease in renal allograft recipients: the role of semiquantitative polymerase chain reaction (Pcr). Nephrology Dialysis Transplantation 10(7): 1198-1205, 1995

Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: the role of semiquantitative polymerase chain reaction (PCR). Nephrology, Dialysis, Transplantation 10(7): 1198-1205, 1995

Diagnosis of cytomegalovirus disease in renal allograft recipients The role of semiquantitative polymerase chain reaction. Nephrology Dialysis Transplantation 10(7): 1198-1205, 1995

Comparison of serology assays and polymerase chain reaction for the monitoring of active cytomegalovirus infection in renal transplant recipients. Transplantation Proceedings 39(9): 2748-2750, 2007

Polymerase Chain Reaction (Pcr) from FicollPurified Polymorphonuclear Leukocytes for Monitoring Cytomegalovirus Infections in Renal Allograft Recipients: Superior Sensitivity and Similar Specificity Compared with Plasma Pcr. The Journal of Infectious Diseases 178(5): 1544-1545, 1998

Polymerase chain reaction from ficoll-purified polymorphonuclear leukocytes for monitoring cytomegalovirus infections in renal allograft recipients Superior sensitivity and similar specificity compared with plasma PCR. Journal of Infectious Diseases 178(5): 1544-1545, 1998

Polymerase chain reaction (PCR) from ficoll-purified polymorphonuclear leukocytes for monitoring cytomegalovirus infections in renal allograft recipients: superior sensitivity and similar specificity compared with plasma PCR. Journal of Infectious Diseases 178(5): 1544-1546, 1998

Prediction and diagnosis of cytomegalovirus disease in renal transplant recipients using qualitative and quantitative polymerase chain reaction. Transplantation 69(5): 985-991, 2001

Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Clinical Transplantation 11(4): 286-293, 1997

Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. Journal of General Virology 76: 309-319, 1995

Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients. Scandinavian Journal of Infectious Diseases 28(4): 347-351, 1996

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70(8): 1174-1180, 2000